IFNG, FCER1A, PCDHB10 expression as a new potential
marker of efficacy in grass pollen allergen-specific
immunotherapy

Jan Romantowski; Agnieszka Maciejewska; Joanna Polańska; Eliza Wasilewska; Krzysztof Specjalski; Marta Chełmińska; Ewa Jassem; Marek Niedoszytko

doi:10.5114/ada.2021.108925

eISSN: 2299-0046
ISSN: 1642-395X

Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii

Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

4/2021
vol. 38

Send email

Copy url:

abstract:

Original paper

IFNG, FCER1A, PCDHB10 expression as a new potential marker of efficacy in grass pollen allergen-specific immunotherapy

Jan Romantowski

¹

,

Agnieszka Maciejewska

²

,

Joanna Polańska

³

,

Eliza Wasilewska

¹

,

Krzysztof Specjalski

¹

,

Marta Chełmińska

¹

,

Ewa Jassem

¹

,

Marek Niedoszytko

¹

Department of Allergology, Medical University of Gdansk, Gdansk, Poland
Department of Forensic Medicine, Medical University of Gdansk, Gdansk, Poland
Faculty of Automatic Control, Electronics, and Computer Science, Silesian University of Technology, Katowice, Poland

Adv Dermatol Allergol 2021; XXXVIII (4): 665–672

DOI: https://doi.org/10.5114/ada.2021.108925

Online publish date: 2021/09/17

View full text Get citation

EndNote

Papers, Reference Manager, RefWorks, Zotero

AMA

Romantowski J, Maciejewska A, Polańska J, et al. IFNG, FCER1A, PCDHB10 expression as a new potential
marker of efficacy in grass pollen allergen-specific
immunotherapy. Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii. 2021;38(4):665-672. doi:10.5114/ada.2021.108925.

APA

Romantowski, J., Maciejewska, A., Polańska, J., Wasilewska, E., Specjalski, K.,  & Chełmińska, M. et al. (2021). IFNG, FCER1A, PCDHB10 expression as a new potential
marker of efficacy in grass pollen allergen-specific
immunotherapy. Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii, 38(4), 665-672. https://doi.org/10.5114/ada.2021.108925

Chicago

Romantowski, Jan, Agnieszka Maciejewska, Joanna Polańska, Eliza Wasilewska, Krzysztof Specjalski, Marta Chełmińska,  and Ewa Jassem et al. 2021. "IFNG, FCER1A, PCDHB10 expression as a new potential
marker of efficacy in grass pollen allergen-specific
immunotherapy". Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii 38 (4): 665-672. doi:10.5114/ada.2021.108925.

Harvard

Romantowski, J., Maciejewska, A., Polańska, J., Wasilewska, E., Specjalski, K., Chełmińska, M., Jassem, E.,  and Niedoszytko, M. (2021). IFNG, FCER1A, PCDHB10 expression as a new potential
marker of efficacy in grass pollen allergen-specific
immunotherapy. Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii, 38(4), pp.665-672. https://doi.org/10.5114/ada.2021.108925

MLA

Romantowski, Jan et al. "IFNG, FCER1A, PCDHB10 expression as a new potential
marker of efficacy in grass pollen allergen-specific
immunotherapy." Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii, vol. 38, no. 4, 2021, pp. 665-672. doi:10.5114/ada.2021.108925.

Vancouver

Romantowski J, Maciejewska A, Polańska J, Wasilewska E, Specjalski K, Chełmińska M et al. IFNG, FCER1A, PCDHB10 expression as a new potential
marker of efficacy in grass pollen allergen-specific
immunotherapy. Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii. 2021;38(4):665-672. doi:10.5114/ada.2021.108925.

Introduction
Allergen-specific immunotherapy (AIT) is the core treatment in allergic rhinitis and asthma. Although widely used, some patients do not benefit from treatment and there is no efficacy objective marker. Aim: To define the profile of gene transcripts during the build-up phase of AIT and their comparison to the control group and then search for a viable efficacy marker in relation to patient symptoms.

Material and methods
AIT was administered in 22 patients allergic to grass pollen. Analysis of 15 selected transcript expression was performed in whole blood samples taken before AIT (sample A) and after reaching the maintenance dose (sample B). The control group included 25 healthy volunteers (sample C). The primary endpoint was Relative Quantification. The gene expression analysis was followed by clinical evaluation with the use of Allergy Control Score (ACS).

Results
Comparison between samples A and B of gene expression showed a significant increase in IFNG expression (p = 0.03). In relation to the control group, pretreatment samples from patients showed higher levels of AFAP1L1 (p = 0.006), COMMD8 (p = 0.001), PIK3CD (p = 0.027) and TWIST2 (p = 0.0003) in univariate analysis. A generalized linear regression model was built according to the Bayesian Information Criterion based on the IFNG, FCER1A and PCDHB10 expression pattern for prediction of the AIT outcome. The model showed a correlation in predicted and observed changes in ACS.

Conclusions
There is a significant change in the expression of IFNG during the build-up phase of AIT. The authors propose an in vitro model of AIT efficacy prediction for further validation.

keywords:

IFNG, FCER1A, PCDHB10 expression as a new potential marker of efficacy in grass pollen allergen-specific immunotherapy

Jan Romantowski 1 , Agnieszka Maciejewska 2 , Joanna Polańska 3 , Eliza Wasilewska 1 , Krzysztof Specjalski 1 , Marta Chełmińska 1 , Ewa Jassem 1 , Marek Niedoszytko 1

allergic rhinitis, asthma, mRNA, allergen

Jan Romantowski

¹

,

Agnieszka Maciejewska

²

,

Joanna Polańska

³

,

Eliza Wasilewska

¹

,

Krzysztof Specjalski

¹

,

Marta Chełmińska

¹

,

Ewa Jassem

¹

,

Marek Niedoszytko

¹